Novotech Appoints Dr. Ian Braithwaite as Vice President, Global Project Management to Lead World-Class Clinical Program Operations
June 24 2024 - 3:53AM
Novotech, the global full-service clinical Contract Research
Organization (CRO) that partners with biotech companies to
accelerate the development of advanced and novel therapeutics at
every phase, has appointed Dr. Ian Braithwaite as Vice President,
Global Project Management.
Novotech COO Michael Stibilj welcomed Dr. Braithwaite to the
team, stating, “Ian brings exceptional leadership and a strategic
clinical background which will be pivotal in advancing our project
management efforts.”
“He also brings extensive expertise in designing, implementing,
and delivering global clinical programs, across various therapeutic
areas, including oncology and rare diseases,” Stibilj said.
Dr. Braithwaite previously held several global roles, most
recently as Senior Vice President & Therapeutic Business Unit
Head at Worldwide Clinical Trials, where he demonstrated his
ability to develop and implement business strategy, drive
operational excellence, profitability and client satisfaction.
Prior to this, Dr. Braithwaite held senior leadership positions
at other renowned organizations, including INC Research and
PPD/Thermo Fisher Scientific, where he was instrumental in
strategic growth initiatives and the development of clinical trial
portfolios.
Ian expressed his delight to be joining Novotech and said he was
honored to lead Global Project Management as the organization
continues to expand its global footprint and capabilities to
support its existing and future biotech clients.
Dr. Braithwaite remarked, “I was drawn to Novotech by the
team’s energy, passion and commitment to project delivery
excellence throughout all phases of clinical development. I'm
even more excited by the prospect of working with a group of
dedicated professionals to deliver high quality global studies for
the benefit of patients and our clients.”
Dr. Braithwaite earned an Honours Degree and PhD in Pharmacology
and Therapeutics at the University of Liverpool. He also holds a
Post graduate Diploma in Clinical Science from the Welsh
School of Pharmacy and Pharmaceutical Sciences.
https://www.linkedin.com/in/ian-braithwaite-46259011/
About Novotech
Novotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical
Contract Research Organization (CRO) focused on partnering with
biotech companies to accelerate the development of advanced and
novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has
received numerous prestigious awards, including the CRO Leadership
Award 2023, the Asia Pacific Cell & Gene Therapy Clinical
Trials Excellence 2023, the Asia-Pacific Contract Research
Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including
laboratories, Phase I facilities, drug development consulting,
regulatory expertise, and has experience with over 5,000 clinical
projects, including Phase I to Phase IV clinical trials and
bioequivalence studies. With a presence in 34 office locations and
a dedicated team of 3,000+ professionals worldwide, Novotech is a
trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member
visit www.Novotech-CRO.com
Media Contact
David James
mediacontact@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427